Uptake of the nitroimidazole drug megazol by African trypanosomes

被引:28
作者
Barrett, MP [1 ]
Fairlamb, AH
Rousseau, B
Chauvière, G
Perié, J
机构
[1] Univ Glasgow, Div Infect Immun, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Dundee, Div Mol Parasitol & Biol Chem, Dept Biochem, Dundee DD1 5EH, Scotland
[3] CEA, Serv Mol Marquees, F-91191 Gif Sur Yvette, France
[4] Univ Toulouse 3, Grp Chim Organ Biol, URA CNRS 470, F-31062 Toulouse, France
基金
英国惠康基金;
关键词
trypanosomiasis; sleeping sickness; chemotherapy; megazol; drug uptake;
D O I
10.1016/S0006-2952(99)00368-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Megazol, CL 64,855 (2-amino-5 [1-methyl-5-nitro-2-imidazolyl]1,3,4-thiazole) has been shown to be extremely effective in clearing experimental infections of African trypanosomes. An unusual amino-purine transporter termed P2, implicated in the transport of both the diamidine and melaminophenyl arsenical classes of drug in Trypanosoma brucei, recognised chemical groups on compounds which are also present on megazol. Megazol interacted with this carrier protein, as judged by its ability to inhibit P2 adenosine transport and to abrogate in vitro arsenical-induced lysis in a dose-dependent manner. However, parasites resistant to melaminophenyl arsenical and diamidine drugs due to lack of the P2 transporter showed no resistance to megazol. This is because passive diffusion represented the major route of entry. Initial rates of uptake were not saturable within the limit of megazol's solubility and did not conform to thermodynamic precepts compatible with carrier-mediated uptake. Adenosine and other P2 transporter substrates, even at high concentration, had little impact on megazol uptake. Uptake was biphasic, with a very rapid equilibration across the membrane followed by a slower accumulation over time. The equilibration phase represented a simple passive diffusion, with the subsequent uptake probably being due to metabolism of the drug. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:615 / 620
页数:6
相关论文
共 27 条
  • [1] The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes
    Barrett, MP
    Fairlamb, AH
    [J]. PARASITOLOGY TODAY, 1999, 15 (04): : 136 - 140
  • [2] The fall and rise of sleeping sickness
    Barrett, MP
    [J]. LANCET, 1999, 353 (9159) : 1113 - 1114
  • [3] A DIAMIDINE-RESISTANT TRYPANOSOMA-EQUIPERDUM CLONE CONTAINS A P2 PURINE TRANSPORTER WITH REDUCED SUBSTRATE AFFINITY
    BARRETT, MP
    ZHANG, ZQ
    DENISE, H
    GIROUD, C
    BALTZ, T
    [J]. MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1995, 73 (1-2) : 223 - 229
  • [4] 2-AMINO-5-(1-METHYL-5-NITRO-2-IMIDAZOLYL)-1,3,4-THIADIAZOLE - A NEW ANTIMICROBIAL AGENT
    BERKELHA.G
    ASATO, G
    [J]. SCIENCE, 1968, 162 (3858) : 1146 - &
  • [5] EFFECT OF MEGAZOL ON TRYPANOSOMA-BRUCEI-BRUCEI ACUTE AND SUBACUTE INFECTIONS IN SWISS MICE
    BOUTEILLE, B
    MARIEDARAGON, A
    CHAUVIERE, G
    DEALBUQUERQUE, C
    ENANGA, B
    DARDE, ML
    VALLAT, JM
    PERIE, J
    DUMAS, M
    [J]. ACTA TROPICA, 1995, 60 (02) : 73 - 80
  • [6] CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153
  • [7] ARSENICAL-RESISTANT TRYPANOSOMES LACK AN UNUSUAL ADENOSINE TRANSPORTER
    CARTER, NS
    FAIRLAMB, AH
    [J]. NATURE, 1993, 361 (6408) : 173 - 176
  • [8] Chauviere G, 1998, J LABELLED COMPD RAD, V41, P47
  • [9] CUNNINGHAM M. P., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P48, DOI 10.1016/0035-9203(62)90088-3
  • [10] DOCAMPO R, 1984, REV INFECT DIS, V6, P223